<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670263</url>
  </required_header>
  <id_info>
    <org_study_id>SZMC-TFI-2019</org_study_id>
    <nct_id>NCT04670263</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)</brief_title>
  <official_title>Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adom Advanced Optical Technologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adom Advanced Optical Technologies Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dry Eye disease signs and symptoms are reduced in patients who receive topical steroids and&#xD;
      topical hyaluronic acid.&#xD;
&#xD;
      AdOM's Tear Film Imager measurements are reproducible and it can diagnose the dry eye disease&#xD;
      state in a single, non-invasive measurement. The Tear Film Imager can provide objective&#xD;
      accurate measurements of the dry eye treatment effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 subjects will be enrolled , 40 of which with positive signs and symptoms of Dry eye and 40&#xD;
      healthy subjects without sign and no symptoms of Dry eye. Healthy and Dry eye groups will be&#xD;
      age- matched.&#xD;
&#xD;
      Over a period of 4 weeks, the subjects diagnosed with dry eye will be treated and as follows:&#xD;
&#xD;
        1. Hylo-comod artificial tears (0.1 % sodium hyaluronate) 8 times a day for 4 weeks&#xD;
&#xD;
        2. Coll STERODEX (Dexamethasone sodium phosphate 0.1% eye drops) 3 times a day for 2 weeks&#xD;
           Healthy subjects will not receive any treatment.&#xD;
&#xD;
      Both groups will be examined at baseline and 4 weeks after baseline measurement.&#xD;
&#xD;
      Treatment results will be measured by both traditional methods and by Tear Film Imager.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinding will take place at the reading center: the patient measurements will be unidentified. Adom's interpreter will not know to which group the examinee belonged to. After the conclusion of the study, the blindness will be removed, and a retrospective statistical analysis will be conducted.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tear film imager measurements with be assessed for reference values for objective tests of the disease with the Tear Film Imager</measure>
    <time_frame>1month</time_frame>
    <description>Tear film imager meuresmend will be assessed during the study visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verify repeatability of Tear film imager measurement</measure>
    <time_frame>2 hours</time_frame>
    <description>The repeatability of TFI will be evaluated by comparing the reported parameters of the two TFI measurements on first visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the clinical measurements of DES to the TFI measurements</measure>
    <time_frame>1month</time_frame>
    <description>The correlation between the clinician's measurements of Dry Eye and the corresponding Tear film imager reported parameters of interest will used to evaluate the association between the two assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the lipid layer thickness</measure>
    <time_frame>from baseline to 1 month</time_frame>
    <description>Change from baseline of the lipid layer thickness as measured by the Tear film imager</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Macu-aqueous layer thickness</measure>
    <time_frame>from baseline to 1 month</time_frame>
    <description>Change from baseline of the Muco-aqueous layer thickness as measured by Tear film imager</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Dry Eye Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who will be diagnosed at baseline with Dry Eye Disease according to standard diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who will be diagnosed at baseline with no Dry Eye Disease according to standard diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tear Film Imager</intervention_name>
    <description>Tear Film Imager recording</description>
    <arm_group_label>Dry Eye Disease</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form.&#xD;
&#xD;
          2. Be at least 18 years of age at the time of enrollment of either sex or any race.&#xD;
&#xD;
          3. Best corrected visual acuity (BCVA) of 0.7 logMAR (ie, 20/100 vision) or better in&#xD;
             each eye as measured using a Snellen chart&#xD;
&#xD;
          4. Intraocular pressure (IOP) in the range of 5 to 22 mmHg in both eyes.&#xD;
&#xD;
          5. DE subjects will be enrolled if they manifest symptoms (OSDI &gt;=13) and signs of&#xD;
             clinically active dry eye disease in either eye, by at least one of:&#xD;
&#xD;
               1. Corneal fluorescein staining - at least severe in one section or moderate at two&#xD;
&#xD;
               2. TBUT =&lt; 10 sec&#xD;
&#xD;
               3. Schirmer wetting of less than 10 mm in 5 min (with anesthesia).&#xD;
&#xD;
          6. Control will be enrolled if they manifest NO symptoms (OSDI &lt;13) and NO signs of&#xD;
             clinically active dry eye disease in either eye, by meeting all the following&#xD;
             criteria's:&#xD;
&#xD;
               1. Corneal fluorescein staining - negative&#xD;
&#xD;
               2. TBUT &gt; 10&#xD;
&#xD;
               3. Schirmer wetting of more than 10 mm in 5 min (with anesthesia).&#xD;
&#xD;
          7. A negative urine pregnancy test if female of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any ocular condition that could affect study parameters (glaucoma, nystagmus,&#xD;
             keratoconus, follicular conjunctivitis, iritis or post LASIK, LASEK or PRK).&#xD;
&#xD;
          2. Have had any ocular infection within the last 30 days and/or have preauricular&#xD;
             lymphadenopathy.&#xD;
&#xD;
          3. Any significant illness that could be expected to interfere with study parameters.&#xD;
&#xD;
          4. Use of any investigational product or device within one month prior to Visit 1 or&#xD;
             during the study period.&#xD;
&#xD;
          5. Concomitant use of any prohibited medication (antihistamines, corticosteroids, all&#xD;
             ocular medications or anti-allergic therapies) during the trial.&#xD;
&#xD;
          6. Any history of, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A&#xD;
             (anti HAV IgM), Any known history of iritis/uveitis, glaucoma, or other chronic&#xD;
             ophthalmologic disorder other than allergic conjunctivitis.&#xD;
&#xD;
          7. History of any ocular surgical procedure within 3 months prior to Visit 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hila Givoni</last_name>
    <phone>972773166784</phone>
    <email>hilag@szmc.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hila Givoni</last_name>
    </contact>
    <investigator>
      <last_name>David Zadok, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

